1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza Group Ltd. Announces Board Changes

01/26/2022 | 01:00am EDT

Lonza Group Ltd. announced that two changes in Lonza's Board of Directors were announced. Dorothée Deuring and Werner J. Bauer have decided not to stand for re-election at the upcoming Annual General Meeting (AGM) on 5 May 2022.


© S&P Capital IQ 2022
All news about LONZA GROUP AG
08:10aLONZA : and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics and..
PU
05/23Switzerland's Lonza to Scale Up Inhalation Capabilities at US Site
MT
05/23LONZA : to Expand Inhalation Capabilities at Tampa Site
PU
05/18Lonza Opens New Facility for Kodiak Sciences' Retinal Diseases Drug
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09LONZA GROUP AG : Ex-dividend day for Distribution from share premium account
FA
05/09LONZA GROUP AG : Ex-dividend day for final dividend
FA
05/06EuroAPI gains on market debut after spin-off from Sanofi
RE
05/05LONZA GROUP AG : Proxy Statments
CO
05/05LONZA GROUP AG : Dividends
CO
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 152 M 6 410 M 6 410 M
Net income 2022 1 064 M 1 108 M 1 108 M
Net cash 2022 423 M 441 M 441 M
P/E ratio 2022 38,7x
Yield 2022 0,59%
Capitalization 41 175 M 42 896 M 42 896 M
EV / Sales 2022 6,62x
EV / Sales 2023 5,90x
Nbr of Employees 16 218
Free-Float 98,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 555,00 CHF
Average target price 796,79 CHF
Spread / Average Target 43,6%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Werner J. Bauer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-27.15%42 618
MODERNA, INC.-48.00%54 740
IQVIA HOLDINGS INC.-28.41%38 497
SEAGEN INC.-13.67%25 649
ICON PUBLIC LIMITED COMPANY-30.17%17 688
CELLTRION, INC.-26.77%16 131